Lupin gets US FDA nod

The company has received green signal from the US regulatory body to market HIV drug


The company will now market generic version of ViiV Healthcare's Epivir Tablets in the US

Lupin has announced that it has received the US Food and Drug Administration (US FDA) approval to market a generic version of ViiV Healthcare's Epivir Tablets, used in treating HIV infection.

According to the company, it has received final approval for its Lamivudine tablets in strengths of 150 mg and 300 mg.

Epivir tablets had annual US sales of $39.7 million as per IMS MAT September 2014 sales data.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email